Saturday 17 October 2026
Export LPCN’s income statement to Excel — free account
Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.56
0.12
−7.14%
Follow LPCN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | — | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 488.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
P/S ratio |
22.14 | 2.28 | 0.00 | 2.19 | 5.15 | — | 0.00 | 0.00 | — | — |
Altman Z-Score |
(7.74) | (0.65) | (10.45) | 4.28 | 4.31 | — | (11.57) | (8.64) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(32.69) | (8.64) | (19.66) | 7.18 | 1.69 | — | (24.07) | (19.23) | — | — |
Beneish M-Score |
23.60 | — | — | 1.57 | — | — | (3.46) | — | — | — |
P/Operating CF |
(14.99) | 15.31 | (7.45) | (19.97) | 9.58 | — | (3.01) | (12.43) | — | — |
P/B ratio |
3.02 | 1.24 | 0.74 | 1.03 | 1.89 | — | 1.59 | 2.94 | — | — |
Price to Tangible BV |
3.02 | 1.24 | 0.74 | 1.03 | 1.89 | — | 1.59 | 2.94 | — | — |
EV/Sales |
16.06 | 0.64 | 1.72 | 0.42 | 2.71 | — | 0.00 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.21 | 0.00 | 12.36 | — | 0.15 | 0.00 | — | — |
EV/Operating CF |
(3.25) | (6.02) | 0.34 | (0.59) | (10.26) | — | 0.17 | (1.47) | — | — |
EV/FCF |
(3.22) | (5.56) | 0.34 | (0.59) | (10.20) | — | 0.17 | (1.46) | — | — |
Quick Ratio |
6.36 | 14.44 | 8.39 | 19.43 | 7.99 | 3.75 | 3.84 | 4.52 | 3.91 | 20.27 |
Current Ratio |
6.68 | 14.75 | 8.69 | 20.34 | 8.26 | 3.85 | 3.95 | 4.63 | 3.97 | 20.52 |
Net Debt/EBITDA |
1.42 | 11.94 | 1.17 | 2.66 | (11.55) | 1.06 | 0.91 | 0.87 | 1.01 | 1.42 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 4.40% | 22.05% | 36.36% | 49.20% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.36 | 1.14 | 1.09 | 0.00 | 0.00 |
Asset Turnover |
0.10 | 0.49 | (0.09) | 0.01 | 0.41 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
Operating CF/Net income |
1.01 | (145.38) | 0.73 | 1.11 | 6.95 | 0.73 | 0.90 | 1.04 | 0.80 | 0.96 |
Capex/Depreciation |
0.00 | 0.14 | 0.01 | 1.19 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.23) |
Interest Coverage |
— | — | — | (447.21) | 15.47 | (46.55) | (16.83) | (24.65) | — | — |
| (54.28%) | 0.04% | (58.40%) | (26.50%) | (2.08%) | (193.85%) | (165.47%) | (82.07%) | (93.26%) | (55.80%) | |
| (48.73%) | 0.04% | (54.02%) | (23.90%) | (1.63%) | (93.15%) | (64.22%) | (50.50%) | (79.68%) | (52.18%) | |
ROIC |
0.00% | 0.00% | 0.00% | (243.95%) | 60.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(66.61%) | 0.04% | (80.37%) | (33.01%) | (1.56%) | (111.84%) | (88.67%) | (71.37%) | (110.73%) | (73.01%) |
Average Days of Receivables |
214.12 | 6.91 | (6.70) | 58.69 | 5.59 | 0.00 | 36.50 | 32.83 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
434.25% | 65.65% | (356.93%) | 1,711.38% | 47.49% | 0.00% | 4,526.18% | 1,510.44% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
190.42% | 44.66% | (172.05%) | 812.50% | 33.02% | 0.00% | 3,392.18% | 1,235.77% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.27% | 3.65% | (22.95%) | 127.22% | 3.74% | 0.00% | 627.76% | 340.58% | 0.00% | 0.00% |
Graham Net Nets |
0.33 | 0.80 | 1.34 | 0.88 | 0.46 | — | 0.63 | 0.34 | — | — |
Graham Number |
0.00 | 0.94 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Earnings Yield |
(22.04%) | 0.20% | (106.30%) | (29.07%) | 0.00% | — | (129.82%) | (42.32%) | — | — |
Free Cash Flow Yield |
(22.53%) | (5.07%) | (78.82%) | (32.95%) | (5.15%) | — | (117.63%) | (43.75%) | — | — |
Revenue per Share |
0.36 | 2.10 | (0.54) | 0.10 | 3.16 | 0.00 | 0.11 | 0.34 | 0.00 | 0.00 |
Operating CF per Share |
(1.79) | (0.23) | (2.25) | (2.29) | (0.86) | (4.67) | (7.67) | (9.62) | (14.16) | (17.03) |
Capex per Share |
0.00 | (0.02) | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) |
Free Cash Flow per Share |
(1.79) | (0.25) | (2.25) | (2.31) | (0.86) | (4.67) | (7.67) | (9.62) | (14.16) | (17.08) |
Cash per Share |
2.74 | 4.05 | 4.18 | 6.22 | 8.73 | 7.53 | 12.53 | 16.13 | 18.21 | 25.00 |
Shareholders Equity per Share |
2.66 | 3.93 | 3.87 | 6.81 | 8.91 | 4.69 | 4.13 | 7.51 | 16.10 | 24.23 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.66 | 3.93 | 3.87 | 6.81 | 8.91 | 4.69 | 4.13 | 7.51 | 16.10 | 24.23 |
Free Cash Flow |
(9.76) | (1.31) | (11.88) | (12.10) | (4.42) | (15.30) | (11.67) | (12.08) | (16.70) | (18.34) |
Working Capital |
14.35 | 20.81 | 20.23 | 32.46 | 40.76 | 18.75 | 14.67 | 16.32 | 18.87 | 25.88 |
Capital Expenditures |
— | (0.09) | (0.01) | (0.13) | (0.01) | — | — | — | — | (0.06) |
Net Current Asset Value |
14.35 | 20.81 | 20.23 | 32.23 | 39.47 | 15.32 | 6.26 | 9.39 | 18.87 | 25.88 |
EV/EBIT |
0.00 | 0.00 | 0.23 | 0.00 | 14.39 | — | 0.15 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.27 | 0.00 | — | 0.00 | 0.00 | — | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 27.38 | — | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(1.27) | (3.98) | (7.96) | (0.86) | 71.67 | 0.00 | (41.36) | (9.46) | (0.95) | 2.48 |
Cash ROIC |
(33.19%) | (3.08%) | (28.01%) | (17.75%) | (4.78%) | (33.56%) | (35.89%) | (30.24%) | (41.29%) | (34.70%) |
Accounts Receivable Turnover |
2.88 | 84.77 | (42.97) | 3.05 | 130.33 | 0.00 | 6.00 | 0.25 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Average Receivables |
0.69 | 0.13 | 0.07 | 0.16 | 0.12 | 0.01 | 0.03 | 1.69 | 1.69 | 0.09 |
Average Payables |
0.62 | 0.83 | 1.00 | 0.94 | 1.44 | 1.39 | 0.93 | 0.63 | 0.42 | 0.38 |
Average Assets |
19.76 | 22.76 | 30.27 | 45.01 | 38.92 | 22.51 | 20.26 | 23.09 | 26.33 | 36.36 |
Average Common Equity |
17.74 | 20.68 | 28.00 | 40.60 | 30.46 | 10.81 | 7.86 | 14.21 | 22.50 | 34.00 |
Columns are period end dates